Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Inclusion Criteria: * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Participants enrolled in any Bayer-sponsored darolutamide feeder study at the time of study closure or primary completion, who are currently receiving darolutamide and are experiencing clinical benefit from treatment. * Participants who have not met any treatment discontinuation criteria in the feeder study protocol. * Willingness to continue practicing acceptable methods of birth control during the study. Exclusion Criteria: * Participant is unable to comply with the requirements of the study. * Negative benefit/ risk ratio as determined by the investigator. * Meet any criteria for treatment discontinuation of the feeder study the participant is coming from.